The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. New President and vice-President for SMA Europe announced

    A new president and a new vice-President for SMA Europe have been elected. SMA Europe held elections for a new President, a new vice-President as well as for a Treasurer, at their annual meeting in April 2016. We are delighted to announce that: Our new President is Marie-Christine Ouillade, Trustee of the Association Française contre les […]


  2. SMA Europe awards new research grants through its 8th call for research proposals

    SMA research receives vital funds from SMA Europe. Based on the recommendations received by its Scientific Advisory Board, SMA Europe awarded a total of 473,000 Euros to 5 cutting-edge SMA research projects through its 8th Call for Research Proposals. The Scientific Advisory Board reviewed and scored 18 very high level SMA research proposals. As only […]


  3. Novartis provides update on LMI070 and its clinical development

    Novartis provides update on LMI070, a potential treatment for SMA Type 1, through the statement below: “We have made the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). Animal safety studies were taking place in parallel with this trial, which is a common […]


  4. Biogen & Ionis Pharmaceuticals Community Statement

    January 14, 2016 Dear members of the SMA community, In response to further requests for information, we want to provide an update on our investigational program to you and the many families around the world who are touched by SMA. Since our last community post, we have made important progress in moving the compound development […]